Duncker Streett & Co. Inc. Raises Position in Amgen, Inc. (NASDAQ:AMGN)

Duncker Streett & Co. Inc. increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,928 shares of the medical research company’s stock after purchasing an additional 72 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Amgen were worth $1,126,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Ruggie Capital Group grew its holdings in Amgen by 297.1% in the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after buying an additional 101 shares in the last quarter. Capital Financial Planning LLC bought a new position in Amgen in the 4th quarter worth approximately $27,000. Massey Quick Simon & CO. LLC grew its holdings in Amgen by 710.5% in the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after buying an additional 135 shares in the last quarter. Next Capital Management LLC bought a new position in Amgen in the 4th quarter worth approximately $33,000. Finally, Essex Investment Management Co. LLC bought a new position in Amgen in the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 77.29% of the company’s stock.

Shares of NASDAQ:AMGN opened at $174.62 on Wednesday. Amgen, Inc. has a one year low of $166.30 and a one year high of $210.19. The firm has a market cap of $107.05 billion, a PE ratio of 12.13, a P/E/G ratio of 2.32 and a beta of 1.13. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating analysts’ consensus estimates of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. During the same quarter in the prior year, the firm earned $3.47 EPS. The company’s quarterly revenue was up .1% compared to the same quarter last year. On average, equities research analysts expect that Amgen, Inc. will post 13.91 EPS for the current year.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total transaction of $386,360.00. Following the sale, the director now directly owns 15,092 shares of the company’s stock, valued at approximately $2,915,472.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 6,000 shares of company stock worth $1,089,180. Company insiders own 0.25% of the company’s stock.

A number of research firms have weighed in on AMGN. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $217.00 target price for the company in a research report on Friday, April 12th. Oppenheimer set a $210.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, May 24th. Cowen restated a “buy” rating and issued a $234.00 target price on shares of Amgen in a research report on Tuesday, February 26th. Cantor Fitzgerald restated a “hold” rating and issued a $221.00 target price on shares of Amgen in a research report on Monday, April 1st. Finally, Mizuho set a $208.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, April 12th. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $208.35.

TRADEMARK VIOLATION NOTICE: This story was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2019/06/12/duncker-streett-co-inc-raises-position-in-amgen-inc-nasdaqamgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: How Does the Quiet Period Work?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.